Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines
Bavarian Nordic said on Thursday it has signed an agreement with the United Nations Children's Fund (UNICEF) for one million doses of its mpox vaccine, Jynneos, for countries in Africa impacted by the disease outbreak.
Bavarian Raises Guidance After Securing More Mpox Vaccine Orders
Bavarian Nordic A/S, one of a few companies with an approved mpox vaccine, is upgrading its financial guidance after securing more orders for its jab as an outbreak rages in Africa.
Bavarian Nordic gains US contract for additional mpox vaccine
The vaccine bulk manufacturing is scheduled for 2025 with the delivery of the freeze-dried doses set for 2026.
Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine
Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said on Tuesday.
WHO prequalifies Bavarian Nordic's vaccine as first shot against mpox
Bavarian Nordic (OTCPK:BVNRY) (OTCPK:BVNKF) on Friday said it received prequalification from the World Health Organization (WHO) for IMVANEX (MVA-BN) as the first mpox vaccine to be added to the WHO prequalification list.
Bavarian Nordic Secures $63M Order for Jynneos Mpox Vaccine
Bavarian Nordic has received a $63 million order from BARDA to produce Jynneos mpox vaccine doses. The contract will support the manufacturing of 1 million freeze-dried vaccines, set for delivery by 2026,
Gavi orders million Mpox vaccine doses from Bavarian Nordic
Gavi, the global vaccine group, announced it will purchase 500,000 doses of Bavarian Nordic’s mpox vaccine. This marks Gavi’s first acquisition of the vaccine to aid in combating an outbreak in parts of Africa.
Mpox Vaccine: Twin Studies Show Bavarian Nordic’s Vaccine Efficacy Declines After One Year
Two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine against the deadly infectious disease wanes “to undetectable levels” in 6-12 months. The vaccine, administered as a 2-dose injection given 4 weeks apart,
Efficacy of Mpox Vaccine Wanes Within a Year, Studies Reveal
The escalating global Mpox outbreak has been met with a concerning revelation. Two distinct studies have indicated that the efficacy of Bavarian Nordic's vaccine, known as Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN),
Study Shows Efficacy Of Mpox Vaccine Wanes To Undetectable Levels Within 6-12 Months
Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months post-vaccination.
Bavarian Nordic Updates FY24 Outlook
(RTTNews) - Bavarian Nordic A/S (BVNRY.PK), Thursday announced an updated guidance for the fiscal year 2024, primarily due to the bulk Mpox vaccine orders secured by the company as well as improved ...
Bavarian Nordic Upgrades its Financial Guidance for 2024
(OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders ...
devdiscourse2d
Bavarian Nordic Secures $63 Million U.S. Government Contract for Vaccine Production
Bavarian Nordic has secured a $63 million contract from the U.S. government to produce the Jynneos vaccine for mpox and ...
Bavarian Nordic A/S: Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 - Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with ...
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September ...
Zacks.com on MSN3d
Are Investors Undervaluing Bavarian Nordic (BVNRY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...